Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease

Katrin Beyer, Jordi Humbert, Anna Ferrer, José I. Lao, Cristina Carrato, Dolores López, Isidro Ferrer, Aurelio Ariza

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)

Abstract

Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration. Three different isoforms (α-synuclein 112, 126, and 140) resulting from alternative splicing have been described so far. The present study explores α-synuclein 126 mRNA expression levels in the prefrontal cortex of six patients with dementia with Lewy bodies, eight patients with Lewy body variant of Alzheimer disease, eight patients with Alzheimer disease, and 10 controls. Relative α-synuclein 126 expression levels were determined by real-time polymerase chain reaction with competimer technology. Alpha-synuclein 126 mRNA expression was markedly decreased in the three dementias in comparison with controls, suggesting an important role of this α-synuclein isoform in the normal brain. © 2006 Lippincott Williams & Wilkins.
Original languageEnglish
Pages (from-to)1327-1330
JournalNeuroReport
Volume17
Issue number12
DOIs
Publication statusPublished - 1 Aug 2006

Keywords

  • α-synuclein isoforms
  • Alzheimer's disease
  • Competimer technology
  • Dementia with Lewy bodies
  • Differential isoform expression
  • mRNA expression

Fingerprint Dive into the research topics of 'Low alpha-synuclein 126 mRNA levels in dementia with Lewy bodies and Alzheimer disease'. Together they form a unique fingerprint.

Cite this